What is the projected market valuation for the South America gene therapy market by 2035?

The projected market valuation for the South America gene therapy market is $916.0 Million by 2035. Read More

What was the market valuation for the South America gene therapy market in 2024?

The market valuation for the South America gene therapy market was $612.0 Million in 2024. Read More

What is the expected CAGR for the South America gene therapy market during the forecast period 2025 - 2035?

The expected CAGR for the South America gene therapy market during the forecast period 2025 - 2035 is 3.73%. Read More

Which companies are considered key players in the South America gene therapy market?

Key players in the South America gene therapy market include Novartis, Gilead Sciences, Sangamo Therapeutics, Bluebird Bio, Spark Therapeutics, CRISPR Therapeutics, Bristol-Myers Squibb, Roche, and AstraZeneca. Read More

What are the market segments for vector type in the South America gene therapy market?

The market segments for vector type include Viral Vector, valued at $540.0 Million, and Non-Viral Vector, valued at $376.0 Million. Read More

What is the valuation for the application segment focusing on oncological disorders in the South America gene therapy market?

The valuation for the application segment focusing on oncological disorders is $182.4 Million. Read More

How does the valuation for rare diseases compare to other applications in the South America gene therapy market?

The valuation for rare diseases is $270.6 Million, which is higher than other applications such as cardiovascular diseases at $90.0 Million. Read More

What are the delivery methods utilized in the South America gene therapy market?

The delivery methods utilized in the South America gene therapy market include In Vivo Gene Therapy, valued at $366.0 Million, and Ex Vivo Gene Therapy, valued at $550.0 Million. Read More

What is the valuation for the gene type segment focusing on tumor suppressors in the South America gene therapy market?

The valuation for the gene type segment focusing on tumor suppressors is $91.6 Million. Read More

What does the growth trend indicate for the South America gene therapy market in the coming years?

The growth trend indicates a steady increase in the South America gene therapy market, with a projected valuation reaching $916.0 Million by 2035. Read More

South America Gene Therapy Market

South America Gene Therapy Market Research Report: Size, Share, Trend Analysis By Therapeutic Area (Oncology, Genetic Disorders, Infectious Diseases, Cardiovascular Diseases, Neurological Disorders), By Technology (Viral Vectors, CRISPR, Gene Editing, RNA Therapy, Non-Viral Methods), By Applications (Research, Clinical, Commercial), By Route of Administration (Intravenous, Intramuscular, Intradermal, Intrathecal, Oral) and By Regional (Brazil, Mexico, Argentina, Rest of South America)- Growth Outlook & Industry Forecast 2025 To 2035

Forecast Period

2025 - 2035

CAGR

3.73%

2024 Market Size

$ 612 Million

2035 Market Size

$ 916 Million

Pharmaceutical ● Updated August 2026 Report ID: MRFR/Pharma/51504-HCR | Pages: 200 | Author: Nidhi Mandole, Rahul Gotadki

Summary Table of Contents Segmentation Download PDF

1 SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS
1. 1.1 EXECUTIVE SUMMARY
  1. 1.1.1 Market Overview
  2. 1.1.2 Key Findings
  3. 1.1.3 Market Segmentation
  4. 1.1.4 Competitive Landscape
  5. 1.1.5 Challenges and Opportunities
  6. 1.1.6 Future Outlook
2 SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE
1. 2.1 MARKET INTRODUCTION
  1. 2.1.1 Definition
  2. 2.1.2 Scope of the study
    1. 2.1.2.1 Research Objective
    2. 2.1.2.2 Assumption
    3. 2.1.2.3 Limitations
2. 2.2 RESEARCH METHODOLOGY
  1. 2.2.1 Overview
  2. 2.2.2 Data Mining
  3. 2.2.3 Secondary Research
  4. 2.2.4 Primary Research
    1. 2.2.4.1 Primary Interviews and Information Gathering Process
    2. 2.2.4.2 Breakdown of Primary Respondents
  5. 2.2.5 Forecasting Model
  6. 2.2.6 Market Size Estimation
    1. 2.2.6.1 Bottom-Up Approach
    2. 2.2.6.2 Top-Down Approach
  7. 2.2.7 Data Triangulation
  8. 2.2.8 Validation
3 SECTION III: QUALITATIVE ANALYSIS
1. 3.1 MARKET DYNAMICS
  1. 3.1.1 Overview
  2. 3.1.2 Drivers
  3. 3.1.3 Restraints
  4. 3.1.4 Opportunities
2. 3.2 MARKET FACTOR ANALYSIS
  1. 3.2.1 Value chain Analysis
  2. 3.2.2 Porter's Five Forces Analysis
    1. 3.2.2.1 Bargaining Power of Suppliers
    2. 3.2.2.2 Bargaining Power of Buyers
    3. 3.2.2.3 Threat of New Entrants
    4. 3.2.2.4 Threat of Substitutes
    5. 3.2.2.5 Intensity of Rivalry
  3. 3.2.3 COVID-19 Impact Analysis
    1. 3.2.3.1 Market Impact Analysis
    2. 3.2.3.2 Regional Impact
    3. 3.2.3.3 Opportunity and Threat Analysis
4 SECTION IV: QUANTITATIVE ANALYSIS
1. 4.1 Life Sciences, BY Vector Type (USD Million)
  1. 4.1.1 Viral Vector
  2. 4.1.2 Non-Viral Vector
2. 4.2 Life Sciences, BY Gene Type (USD Million)
  1. 4.2.1 Antigen
  2. 4.2.2 Cytokine
  3. 4.2.3 Tumor Suppressor
  4. 4.2.4 Suicide
  5. 4.2.5 Deficiency
  6. 4.2.6 Growth Factors
  7. 4.2.7 Receptors
  8. 4.2.8 Others
3. 4.3 Life Sciences, BY Application (USD Million)
  1. 4.3.1 Oncological Disorders
  2. 4.3.2 Rare Diseases
  3. 4.3.3 Cardiovascular Diseases
  4. 4.3.4 Neurological Disorders
  5. 4.3.5 Infectious Diseases
  6. 4.3.6 Others
4. 4.4 Life Sciences, BY Delivery Method (USD Million)
  1. 4.4.1 In Vivo Gene Therapy
  2. 4.4.2 Ex Vivo Gene Therapy
5 SECTION V: COMPETITIVE ANALYSIS
1. 5.1 Competitive Landscape
  1. 5.1.1 Overview
  2. 5.1.2 Competitive Analysis
  3. 5.1.3 Market share Analysis
  4. 5.1.4 Major Growth Strategy in the Life Sciences
  5. 5.1.5 Competitive Benchmarking
  6. 5.1.6 Leading Players in Terms of Number of Developments in the Life Sciences
  7. 5.1.7 Key developments and growth strategies
    1. 5.1.7.1 New Product Launch/Service Deployment
    2. 5.1.7.2 Merger & Acquisitions
    3. 5.1.7.3 Joint Ventures
  8. 5.1.8 Major Players Financial Matrix
    1. 5.1.8.1 Sales and Operating Income
    2. 5.1.8.2 Major Players R&D Expenditure. 2023
2. 5.2 Company Profiles
  1. 5.2.1 Novartis (CH)
    1. 5.2.1.1 Financial Overview
    2. 5.2.1.2 Products Offered
    3. 5.2.1.3 Key Developments
    4. 5.2.1.4 SWOT Analysis
    5. 5.2.1.5 Key Strategies
  2. 5.2.2 Gilead Sciences (US)
    1. 5.2.2.1 Financial Overview
    2. 5.2.2.2 Products Offered
    3. 5.2.2.3 Key Developments
    4. 5.2.2.4 SWOT Analysis
    5. 5.2.2.5 Key Strategies
  3. 5.2.3 Sangamo Therapeutics (US)
    1. 5.2.3.1 Financial Overview
    2. 5.2.3.2 Products Offered
    3. 5.2.3.3 Key Developments
    4. 5.2.3.4 SWOT Analysis
    5. 5.2.3.5 Key Strategies
  4. 5.2.4 Bluebird Bio (US)
    1. 5.2.4.1 Financial Overview
    2. 5.2.4.2 Products Offered
    3. 5.2.4.3 Key Developments
    4. 5.2.4.4 SWOT Analysis
    5. 5.2.4.5 Key Strategies
  5. 5.2.5 Spark Therapeutics (US)
    1. 5.2.5.1 Financial Overview
    2. 5.2.5.2 Products Offered
    3. 5.2.5.3 Key Developments
    4. 5.2.5.4 SWOT Analysis
    5. 5.2.5.5 Key Strategies
  6. 5.2.6 CRISPR Therapeutics (CH)
    1. 5.2.6.1 Financial Overview
    2. 5.2.6.2 Products Offered
    3. 5.2.6.3 Key Developments
    4. 5.2.6.4 SWOT Analysis
    5. 5.2.6.5 Key Strategies
  7. 5.2.7 Bristol-Myers Squibb (US)
    1. 5.2.7.1 Financial Overview
    2. 5.2.7.2 Products Offered
    3. 5.2.7.3 Key Developments
    4. 5.2.7.4 SWOT Analysis
    5. 5.2.7.5 Key Strategies
  8. 5.2.8 Roche (CH)
    1. 5.2.8.1 Financial Overview
    2. 5.2.8.2 Products Offered
    3. 5.2.8.3 Key Developments
    4. 5.2.8.4 SWOT Analysis
    5. 5.2.8.5 Key Strategies
  9. 5.2.9 AstraZeneca (GB)
    1. 5.2.9.1 Financial Overview
    2. 5.2.9.2 Products Offered
    3. 5.2.9.3 Key Developments
    4. 5.2.9.4 SWOT Analysis
    5. 5.2.9.5 Key Strategies
3. 5.3 Appendix
  1. 5.3.1 References
  2. 5.3.2 Related Reports
6 LIST OF FIGURES
1. 6.1 MARKET SYNOPSIS
2. 6.2 SOUTH AMERICA MARKET ANALYSIS BY VECTOR TYPE
3. 6.3 SOUTH AMERICA MARKET ANALYSIS BY GENE TYPE
4. 6.4 SOUTH AMERICA MARKET ANALYSIS BY APPLICATION
5. 6.5 SOUTH AMERICA MARKET ANALYSIS BY DELIVERY METHOD
6. 6.6 KEY BUYING CRITERIA OF LIFE SCIENCES
7. 6.7 RESEARCH PROCESS OF MRFR
8. 6.8 DRO ANALYSIS OF LIFE SCIENCES
9. 6.9 DRIVERS IMPACT ANALYSIS: LIFE SCIENCES
10. 6.10 RESTRAINTS IMPACT ANALYSIS: LIFE SCIENCES
11. 6.11 SUPPLY / VALUE CHAIN: LIFE SCIENCES
12. 6.12 LIFE SCIENCES, BY VECTOR TYPE, 2024 (% SHARE)
13. 6.13 LIFE SCIENCES, BY VECTOR TYPE, 2024 TO 2035 (USD Million)
14. 6.14 LIFE SCIENCES, BY GENE TYPE, 2024 (% SHARE)
15. 6.15 LIFE SCIENCES, BY GENE TYPE, 2024 TO 2035 (USD Million)
16. 6.16 LIFE SCIENCES, BY APPLICATION, 2024 (% SHARE)
17. 6.17 LIFE SCIENCES, BY APPLICATION, 2024 TO 2035 (USD Million)
18. 6.18 LIFE SCIENCES, BY DELIVERY METHOD, 2024 (% SHARE)
19. 6.19 LIFE SCIENCES, BY DELIVERY METHOD, 2024 TO 2035 (USD Million)
20. 6.20 BENCHMARKING OF MAJOR COMPETITORS
7 LIST OF TABLES
1. 7.1 LIST OF ASSUMPTIONS
7.1.1
1. 7.2 South America MARKET SIZE ESTIMATES; FORECAST
  1. 7.2.1 BY VECTOR TYPE, 2025-2035 (USD Million)
  2. 7.2.2 BY GENE TYPE, 2025-2035 (USD Million)
  3. 7.2.3 BY APPLICATION, 2025-2035 (USD Million)
  4. 7.2.4 BY DELIVERY METHOD, 2025-2035 (USD Million)
2. 7.3 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL
7.3.1
1. 7.4 ACQUISITION/PARTNERSHIP
7.4.1

Certified Researchers

Customize Report

South America South America Gene Therapy Market Segmentation

South America Gene Therapy Market By Vector Type (USD Million, 2025-2035)

Viral Vector
Non-Viral Vector

South America Gene Therapy Market By Gene Type (USD Million, 2025-2035)

Antigen
Cytokine
Tumor Suppressor
Suicide
Deficiency
Growth Factors
Receptors
Others

South America Gene Therapy Market By Application (USD Million, 2025-2035)

Oncological Disorders
Rare Diseases
Cardiovascular Diseases
Neurological Disorders
Infectious Diseases
Others

South America Gene Therapy Market By Delivery Method (USD Million, 2025-2035)

In Vivo Gene Therapy
Ex Vivo Gene Therapy

Certified Researchers

Customize Report

Customer Stories

“This is really good guys. Excellent work on a tight deadline. I will continue to use you going forward and recommend you to others. Nice job”

Noah Malgeri Co-Founder

“Thanks. It’s been a pleasure working with you, please use me as reference with any other Intel employees.”

Joseph Aguayo Sales Operations & Pricing Manager

“Thanks for sending the report it gives us a good global view of the Betaïne market.”

Peter Groot koerkamp Account and Business Manager

“Thank you, this will be very helpful for OQS.”

La Terria Dodd Program Support Specialist

“We found the report very insightful! we found your research firm very helpful. I'm sending this email to secure our future business.”

Younghwan Choi Senior Retail Manager

“I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.”

Mark Irwin Management Consultant

“I have been reading the first document or the study, ,the Global HVAC and FP market report 2021 till 2026. Must say, good info! I have not gone in depth at all parts, but got a good indication of the data inside!”

Rob Kooiker Group Product Manager HVAC & Fire Protection GMA

“We got the report in time, we really thank you for your support in this process. I also thank to all of your team as they did a great job.”

Akif Moroglu Strategy & Business Development Director

“The Automotive 48V ECU Components Procurement Intelligence Study” was a complex project, but the Market Research Future (MRFR) team handled it with quality, agility, and customer-centricity. They delivered all requested data on time and within the agreed scope. The team, including Shubhendra Anand and Rahul Gotadki, was always readily available to clarify questions and swiftly implement necessary adjustments, driving the project to a successful conclusion within a very demanding timeframe.
I would also like to specifically commend Akshay Agarwal for his responsiveness and support at every stage—from our initial inquiry on May 6th through to final delivery on June 18th. His dedication made the entire process seamless.”